Skip to main content
Equibles
TNDM logo

TNDM · Tandem Diabetes Care Inc · Documents

Track TNDM — free

Use TNDM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNDM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.07 +2.56 (+14.62%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.40B
Shares
69.79M
Volume · Nov 13 4.4M Avg daily vol (3M) 2.21M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.01B up 7.9% 10-K filed Feb 19, 2026 Quarterly report FY2026 Q3 Revenue $283.69M up 13.8% 10-Q filed Nov 5, 2026 Latest results Third-quarter sales rise 14% as operating loss narrows 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 13
Current report 8-K Events of Nov 12
Tandem Mobi tubeless system cleared for up to 7 days

Tandem Diabetes Care received 510(k) clearance for Tandem Mobi’s tubeless cartridge and infusion set, supporting up to 7 days of wear and 3 days of cartridge use. U.S. launch is planned for the first half of 2027.

Other events
3 source passages
On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1). Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States. Open the document at this passage
Nov 5
Earnings call
Revenue grew 14%; leadership transition announced

Tandem reported worldwide revenue grew 14% year-over-year to $284 million, announced a CEO retirement at the end of 2026 and named Jeanette Bankus president and CEO.

2 source passages
worldwide revenue grew 14% year-over-year to $284 million we celebrate John Sheraton's accomplished tenure as he prepares to retire at the end of 2026, and we are thrilled to welcome Jeanette Bankus as Tandem's next president and CEO Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales reach $283.7 million, gross margin 57%

Tandem Diabetes Care reported third-quarter sales of $283.7 million, including $92.6 million internationally, and a 57% gross margin, compared with $249.3 million and 54%, amid continued inventory constraints from a key supplier.

Revenue $283.69M ▲ 13.8% Net loss $7.09M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. For the three months ended September 30, 2026, we shipped approximately 33,000 pumps worldwide. Sales were $283.7 million, which included $92.6 million of international sales. Sales were $249.3 million for the three months ended September 30, 2025, which included $73.6 million of international sales. The gross margins for the three months ended September 30, 2026 and 2025 were 57% and 54%, respectively. Open the document at this passage
Nov 5
Current report 8-K
Third-quarter sales rise 14% as operating loss narrows

Tandem Diabetes Care reported third-quarter sales of $283.7 million, up 14%, gross margin of 57% and an operating loss of $2.4 million versus $22.9 million. Adjusted EBITDA reached $18.0 million, compared with $2.8 million.

Financial results
5 source passages
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results Sales: Worldwide sales increased 14% to $283.7 million, compared to $249.3 million on a reported basis and in constant currency(1). Gross profit was $160.4 million, compared to $134.3 million. Gross margin was 57%, compared to 54%. Operating loss was $2.4 million, or negative 1% of sales, compared to operating loss of $22.9 million, or negative 9% of sales. Adjusted EBITDA(1) was $18.0 million, or 6% of sales, compared to $2.8 million, or 1% of sales. Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $254.56M ▲ 5.8% Net loss $21.17M Diluted EPS -$0.31
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $247.22M ▲ 5.5% Net loss $20.39M Diluted EPS -$0.30
Feb 19
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.01B ▲ 7.9% Net loss $204.71M Diluted EPS -$3.04
2025
Feb 26
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $940.2M ▲ 25.7% Net loss $96.03M Diluted EPS -$1.47
2024
Showing 1–50 of 148 documents
Key facts CIK 1438133 CUSIP 875372203 13F (30d) 215 filings 190 filers Visit website Investor relations